Opening Plenary for BIO-Windhover Partnering Conference Features Leading Biotech Researchers, CEOs

  • Contact: Carrie Housman
    (202) 962-9200
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (April 4, 2002) – The Biotechnology Industry Organization (BIO) has joined with a leading health-care business information provider, Windhover Information, to host the first BIO-Windhover Partnering Conference.

The goal of BIO-Windhover is to bring together pharmaceutical and biotech decision makers in a format designed to provide maximum opportunity for focused partnering discussions. In addition to pre-scheduled meetings, on-site partnering facilitation and networking receptions, the conference will feature four plenary sessions and panels on the most pressing issues facing life-science business development professionals.

The partnering event will be held at the Ritz-Carlton in Washington, April 24-26, and will feature senior partnering delegations from more than 130 life-sciences companies, including Amgen, AstraZeneca, Aventis, Baxter, Bristol-Myers Squibb, Genentech, Genzyme, GlaxoSmithKline, Novartis, Pfizer, Schering-Plough and Wyeth Pharmaceuticals. For a complete list of participating companies, visit the BIO-Windhover section of www.bio.org or the meeting Web site at www.biowindhover.com.

OPENING PLENARY
WHAT: The Future of Pharmaceutical Research: Challenges and Solutions
WHEN: Thursday, April 25, 8:30 – 10 a.m.
WHO:
Robert Tepper, chief scientific officer and executive vice president of discovery, Millennium Pharmaceuticals Inc.
Goran Ando, president of research and development, Pharmacia Corp.
Richard DiMarchi, group vice president of research technologies, Eli Lilly and Co.
William Haseltine, chairman and CEO, Human Genome Sciences Inc.
WHERE: Ritz-Carlton, Ballroom Salon 1

FINANCING PLENARY
WHAT: VC, Fund Manager, and Big Pharma Perspective
WHEN: Thursday, April 25, 1:30 – 3 p.m.
WHO:
Scott Sacane, Perseus Soros Biopharmaceutical Fund
Michael Lytton, general partner, Oxford Bioscience Partners
Nicholas Galakatos, general partner, MPM Capital
Karen Bernstein, chairman and editor-in-chief, BioCentury
Carl Gordon, general partner, OrbiMed Advisors LLC (invited)
WHERE: Ritz-Carlton, Ballroom Salon 3

Press registration is complimentary for credentialed members of the news media. Registration and other information can be found at www.bio.org. Contact Carrie Housman at (202) 962-9200 with any questions.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

# # #

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.